HRTX Latest Headlines

Heron Therapeutics Projects Continued Growth as ZYNRELEF and APONVIE Drive Record Acute Care Revenue

Market Chameleon (Thu, 26-Feb 10:37 AM)

Heron Therapeutics: Profitable Growth Outlook and Acute Care Momentum Underpin Buy Rating and $3 Target

at www.tipranks.com (Thu, 26-Feb 4:05 PM)

Heron Therapeutics outlines $173M–$183M 2026 sales targets amid acute care momentum and expanded commercial investment

at seekingalpha.com (Thu, 26-Feb 3:09 PM)

Analysts’ Top Healthcare Picks: Heron Therapeutics (HRTX), Viridian Therapeutics (VRDN)

at www.tipranks.com (Thu, 26-Feb 1:20 PM)

Heron Therapeutics reports mixed Q4 results; introduces FY26 outlook

at seekingalpha.com (Thu, 26-Feb 8:05 AM)

Heron Therapeutics Q4 2025 Earnings Preview

at seekingalpha.com (Wed, 25-Feb 10:00 AM)

ZYNRELEF Drives Heron Therapeutics’ Strong Q4 Revenue Growth—What Stands Out in the 2025 Preliminary Results?

Market Chameleon (Fri, 9-Jan 11:15 AM)